Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Atsena & Nippon Shinyaku Partner on ATSN-101
Atsena Therapeutics, Inc. and Nippon Shinyaku Co., Ltd. have entered an exclusive licensing agreement to advance and commercialize ATSN-101, an investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), in both the United States and Japan. ATSN-101 is designed…
Eyenovia and SGN Nanopharma to Develop Dry Eye Treatment
Eyenovia and SGN Nanopharma have announced a new collaboration to develop a treatment for chronic dry eye disease. Eyenovia, known for its two FDA-approved products and a late-stage asset in pediatric progressive myopia, will work with SGN Nanopharma to develop…
Novaliq’s Vevizye® Receives Positive CHMP Opinion for DED
Novaliq announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the granting of a marketing authorization for Vevizye® in the European Union. This therapy is designed to treat moderate…
Elon Musk’s Blindsight Implant Faces Skepticism from Researchers
Elon Musk recently announced on X that Blindsight, a cortical implant to restore vision, would have low resolution at first “but may ultimately exceed normal human vision.” Skepticism from University of Washington Research New research from the University of Washington…
Link Between Proteins in Tears and Pain After Eye Surgery
In a study published in the Journal of Proteome Research, researchers from Oregon Health & Science University (OHSU) have identified a connection between specific proteins found in patients’ tears and persistent pain experienced months after eye surgery. This discovery could…
New Insights on Retinoblastoma Treatment
Recent research presented at the Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting underscores significant improvements in treating retinoblastoma, a rare eye cancer affecting young children. The study reveals that advancements in treatment over the past 15 years have notably…
Nicox Concludes U.S. Recruitment for Phase 3 NCX 470 Trial
Nicox announced the recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial of NCX 470. This milestone marks a significant step in evaluating the safety and efficacy of NCX 470 for patients…
Trial Results for Susvimo Show Sustained Efficacy in DME and DR
Genentech and Roche released compelling 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL, marking a significant development in the treatment landscape for diabetic macular edema (DME) and diabetic retinopathy (DR). Reintroduction of…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…